drugset / Trial / NCT01927198
RDEA3170 Monotherapy in Subjects With Gout
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-05
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verinurad | Small molecule | 5 mg | — |
| Subject | Verinurad | Small molecule | 10 mg | — |
| Subject | Verinurad | Small molecule | 12.5 mg | — |